AGIO Halts Tebapivat Development in Myelodysplastic Syndromes

Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficacy goals, shifting focus ...

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Results did not meet predefined threshold to support further development in LR-MDSTebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- ...
sharewise

AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate

Agios Pharmaceuticals AGIO has inked an agreement with Oscotec, a South Korea-based biotech, in-licensing exclusive global ...

Agios Pharmaceuticals, Inc.: Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Results did not meet predefined threshold to support further development in LR-MDSTebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- ...

Agios scraps blood cancer drug program after study miss

May 29 (Reuters) - Agios Pharmaceuticals said on Friday it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show enough benefit, marking a ...

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemiaMitapivat is now approved for thalassemia in the U.S., ...